211 related articles for article (PubMed ID: 31694094)
41. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
Ramadan WH; Kabbara WK; El Khoury GM; Al Assir SA
Int J Chron Obstruct Pulmon Dis; 2015; 10():2347-56. PubMed ID: 26586940
[TBL] [Abstract][Full Text] [Related]
42. Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials.
Ferguson GT; Buhl R; Bothner U; Hoz A; Voß F; Anzueto A; Calverley PMA
Respir Med; 2018 Oct; 143():67-73. PubMed ID: 30261995
[TBL] [Abstract][Full Text] [Related]
43. Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies.
Ferguson GT; Maltais F; Karpel J; Bothner U; Kloer I; Trampisch M; Buhl R
NPJ Prim Care Respir Med; 2020 Dec; 30(1):53. PubMed ID: 33277507
[TBL] [Abstract][Full Text] [Related]
44. Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD.
Andreas S; McGarvey L; Bothner U; Trampisch M; de la Hoz A; Fležar M; Buhl R; Alter P
Int J Chron Obstruct Pulmon Dis; 2020; 15():1935-1944. PubMed ID: 32848379
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study.
Kawachi S; Fujimoto K
Int J Chron Obstruct Pulmon Dis; 2019; 14():1167-1176. PubMed ID: 31213796
[No Abstract] [Full Text] [Related]
46. No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD.
Andreas S; Bothner U; de la Hoz A; Kloer I; Trampisch M; Alter P
Int J Chron Obstruct Pulmon Dis; 2020; 15():1945-1953. PubMed ID: 32848380
[TBL] [Abstract][Full Text] [Related]
47. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
[TBL] [Abstract][Full Text] [Related]
48. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
49. Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO
Wedzicha JA; Buhl R; Singh D; Vogelmeier CF; de la Hoz A; Xue W; Anzueto A; Calverley PMA
Adv Ther; 2020 Oct; 37(10):4266-4279. PubMed ID: 32776202
[TBL] [Abstract][Full Text] [Related]
50. 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD.
van Noord JA; Smeets JJ; Drenth BM; Rascher J; Pivovarova A; Hamilton AL; Cornelissen PJ
Pulm Pharmacol Ther; 2011 Dec; 24(6):666-72. PubMed ID: 21839850
[TBL] [Abstract][Full Text] [Related]
51. Tiotropium/Olodaterol: A Review in COPD.
Dhillon S
Drugs; 2016 Jan; 76(1):135-46. PubMed ID: 26683033
[TBL] [Abstract][Full Text] [Related]
52. First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease.
Takahashi K; Uchida M; Kato G; Takamori A; Kinoshita T; Yoshida M; Tajiri R; Kojima K; Inoue H; Kobayashi H; Sadamatsu H; Tashiro H; Tanaka M; Hayashi S; Kawaguchi A; Kimura S; Sueoka-Aragane N; Kawayama T;
Int J Chron Obstruct Pulmon Dis; 2020; 15():2115-2126. PubMed ID: 32982204
[TBL] [Abstract][Full Text] [Related]
53. β-Blockers in COPD: A Cohort Study From the TONADO Research Program.
Maltais F; Buhl R; Koch A; Amatto VC; Reid J; Grönke L; Bothner U; Voß F; McGarvey L; Ferguson GT
Chest; 2018 Jun; 153(6):1315-1325. PubMed ID: 29355547
[TBL] [Abstract][Full Text] [Related]
54. A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease.
Joos GF; Aumann JL; Coeck C; Korducki L; Hamilton AL; Kunz C; Aalbers R
Respir Med; 2015 May; 109(5):606-15. PubMed ID: 25776199
[TBL] [Abstract][Full Text] [Related]
55. Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study.
Ichinose M; Nishimura M; Akimoto M; Kurotori Y; Zhao Y; de la Hoz A; Mishima M
Int J Chron Obstruct Pulmon Dis; 2018; 13():2147-2156. PubMed ID: 30034230
[TBL] [Abstract][Full Text] [Related]
56. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness
Maltais F; Aumann JL; Kirsten AM; Nadreau É; Macesic H; Jin X; Hamilton A; O'Donnell DE
Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30655277
[TBL] [Abstract][Full Text] [Related]
57. Effect of Bronchodilation, Exercise Training, and Behavior Modification on Symptoms and Physical Activity in Chronic Obstructive Pulmonary Disease.
Troosters T; Maltais F; Leidy N; Lavoie KL; Sedeno M; Janssens W; Garcia-Aymerich J; Erzen D; De Sousa D; Korducki L; Hamilton A; Bourbeau J
Am J Respir Crit Care Med; 2018 Oct; 198(8):1021-1032. PubMed ID: 29664681
[TBL] [Abstract][Full Text] [Related]
58. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD.
O'Donnell DE; Casaburi R; Frith P; Kirsten A; De Sousa D; Hamilton A; Xue W; Maltais F
Eur Respir J; 2017 Apr; 49(4):. PubMed ID: 28424359
[TBL] [Abstract][Full Text] [Related]
59. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.
Timmer W; Moroni-Zentgraf P; Cornelissen P; Unseld A; Pizzichini E; Buhl R
Respir Med; 2015 Mar; 109(3):329-38. PubMed ID: 25661281
[TBL] [Abstract][Full Text] [Related]
60. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
